|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
KX2-391
Description of KX2-391: KX2-391 is an orally bioavailable small molecule Src
kinase inhibitor with potential antineoplastic activity. Unlike other
Src kinase inhibitors which bind to the ATP-binding site, Src kinase
inhibitor KX2-391 specifically binds to the peptide substrate binding
site of Src kinase; inhibition of kinase activity may result in the
inhibition of primary tumor growth and the suppression of metastasis.
Src tyrosine kinases are upregulated in many tumor cells and play
important roles in tumor cell proliferation and metastasis. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer: Kinex
Pharmaceuticals
|
MedKoo Code#: 201686
|
|
Name:
KX2-391
|
|
CAS#: 897016-82-9 (KX2-391 free
base); 1038395-65-1
(KX2-391 hydrochloride salt)
Synonym:
KX01; KX2-391.
IUPAC/Chemical name:
(E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Chemical Formula: C26H29N3O3
Exact Mass: 431.22089
Molecular Weight: 431.53
Elemental Analysis: C, 72.37; H, 6.77; N,
9.74; O, 11.12
|
|
Availability and price:
This agent is available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
1. Hangauer, David G.; Smolinski, Michael; Bu,
Yahao; Kazim, Latif; Qu, Jun. Photoaffinity labeling studies to better
define the mechanism of action for Phase II oncology drug KX2-391.
Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA,
United States, March 21-25, 2010 (2010), MEDI-295. CODEN: 69MML8 AN
2010:344831
2. Hangauer, David G., Jr.; Patra, Debasis; Cody, Jeremy A.; Palmer,
Grant J.; Isbester, Paul K.; Salsbury, Jonathon. Preparation of
2-[5-[4-(2-morpholinoethoxy)phenyl]pyridin-2-yl]-N-benzylacetamide
mesylate polymorph Form A with improved stability. U.S. Pat. Appl. Publ.
(2009), 68pp., Cont.-in-part of U.S. Ser. No. 154,056. CODEN: USXXCO US
2009318450 A1 20091224 CAN 152:75049 AN 2009:1599300
3. Lau, Grace M.; Lau, Gillian M.; Yu, Guo-Liang; Gelman, Irwin H.;
Gutowski, Alan; Hangauer, David; Fang, Jane W. S. Expression of Src and
FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on
Hepatocellular Carcinoma In Vitro. Digestive Diseases and Sciences
(2009), 54(7), 1465-1474. CODEN: DDSCDJ ISSN:0163-2116. AN 2009:677742
4. Hangauer, David G., Jr.; Coughlin, Daniel; Cody, Jeremy A.; Gale,
Jonathan. Synthesis of [(morpholinoethoxy)phenyl]pyridine KX2-391
compositions for modulating a kinase cascade. U.S. Pat. Appl. Publ.
(2008), 44 pp., Cont.-in-part of U.S. Ser. No. 5,792. CODEN: USXXCO US
2008287436 A1 20081120 CAN 149:556637 AN 2008:1398805
5. Hangauer, David G.; Coughlin, Daniel; Cody, Jeremy A.; Gale,
Jonathan. Methods for preparing
N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide
[KX2-391] for use in modulating a kinase cascade. PCT Int. Appl. (2008),
94pp. CODEN: PIXXD2 WO 2008082637 A1 20080710 CAN 149:152968 AN
2008:831758
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
